Advanz Pharma (OTCMKTS:CXRXF) Lowered to Sell at Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Advanz Pharma (OTCMKTS:CXRXF) from a hold rating to a sell rating in a report released on Monday morning, Zacks.com reports.

According to Zacks, “Advanz Pharma Corp. is a specialty pharmaceutical company. It operates primarily in Bridgetown, Barbados; London, England and Mumbai, through its subsidiaries. Advanz Pharma Corp., formerly known as Concordia International Corp., is based in LONDON, UNITED KINGDOM. “

Separately, ValuEngine upgraded Advanz Pharma from a buy rating to a strong-buy rating in a research report on Wednesday, September 4th.

Shares of CXRXF stock opened at $13.93 on Monday. The firm has a market cap of $688.16 million, a P/E ratio of 1.18 and a beta of 0.53. Advanz Pharma has a fifty-two week low of $9.32 and a fifty-two week high of $34.95. The business’s 50 day moving average price is $12.01 and its 200-day moving average price is $15.00. The company has a debt-to-equity ratio of 9.26, a quick ratio of 1.98 and a current ratio of 2.33.

Advanz Pharma (OTCMKTS:CXRXF) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.42) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.03. The firm had revenue of $131.08 million for the quarter, compared to analyst estimates of $127.00 million. Advanz Pharma had a negative return on equity of 60.90% and a net margin of 322.43%. As a group, equities analysts predict that Advanz Pharma will post -2.09 EPS for the current year.

About Advanz Pharma

ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Featured Story: What is insider trading?

Get a free copy of the Zacks research report on Advanz Pharma (CXRXF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

AQR Capital Management LLC Reduces Holdings in Senseonics Holdings Inc
AQR Capital Management LLC Reduces Holdings in Senseonics Holdings Inc
SOTHERLY HOTELS/SH SH  Upgraded by Zacks Investment Research to Hold
SOTHERLY HOTELS/SH SH Upgraded by Zacks Investment Research to Hold
Solaredge Technologies  Lowered to Hold at Zacks Investment Research
Solaredge Technologies Lowered to Hold at Zacks Investment Research
Resonant  Upgraded to “Hold” at Zacks Investment Research
Resonant Upgraded to “Hold” at Zacks Investment Research
Portola Pharmaceuticals  PT Lowered to $44.00
Portola Pharmaceuticals PT Lowered to $44.00
UltraNote Coin Reaches Market Cap of $13,486.00
UltraNote Coin Reaches Market Cap of $13,486.00


© 2006-2019 Ticker Report